WO1999036536A9 - Methodes et compositions permettant de modifier la sensibilite des tissus face aux lesions immunitaires, a la mort cellulaire programmee et a la clairance par le systeme reticulo-endothelial - Google Patents
Methodes et compositions permettant de modifier la sensibilite des tissus face aux lesions immunitaires, a la mort cellulaire programmee et a la clairance par le systeme reticulo-endothelialInfo
- Publication number
- WO1999036536A9 WO1999036536A9 PCT/US1999/001087 US9901087W WO9936536A9 WO 1999036536 A9 WO1999036536 A9 WO 1999036536A9 US 9901087 W US9901087 W US 9901087W WO 9936536 A9 WO9936536 A9 WO 9936536A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- scramblase
- cell
- protein
- cells
- human
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 71
- 210000000865 mononuclear phagocyte system Anatomy 0.000 title description 15
- 238000003782 apoptosis assay Methods 0.000 title description 14
- 230000005522 programmed cell death Effects 0.000 title description 14
- 230000006378 damage Effects 0.000 title description 6
- 208000027418 Wounds and injury Diseases 0.000 title description 5
- 208000014674 injury Diseases 0.000 title description 5
- 239000000203 mixture Substances 0.000 title description 3
- 210000004027 cell Anatomy 0.000 claims abstract description 301
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 120
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 104
- 230000014509 gene expression Effects 0.000 claims abstract description 55
- 230000000694 effects Effects 0.000 claims abstract description 46
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 24
- 201000011510 cancer Diseases 0.000 claims abstract description 24
- 230000001965 increasing effect Effects 0.000 claims abstract description 23
- 230000003247 decreasing effect Effects 0.000 claims abstract description 10
- 230000035899 viability Effects 0.000 claims abstract description 8
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 6
- 230000001394 metastastic effect Effects 0.000 claims abstract description 6
- 206010061289 metastatic neoplasm Diseases 0.000 claims abstract description 6
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 5
- 239000002299 complementary DNA Substances 0.000 claims description 43
- 230000006907 apoptotic process Effects 0.000 claims description 42
- 101001134456 Homo sapiens Pancreatic triacylglycerol lipase Proteins 0.000 claims description 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 25
- 238000004458 analytical method Methods 0.000 claims description 19
- 108020004414 DNA Proteins 0.000 claims description 18
- 229920001184 polypeptide Polymers 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 238000001262 western blot Methods 0.000 claims description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 13
- 210000005260 human cell Anatomy 0.000 claims description 12
- 238000001890 transfection Methods 0.000 claims description 12
- 238000000684 flow cytometry Methods 0.000 claims description 10
- 239000000499 gel Substances 0.000 claims description 10
- 238000000636 Northern blotting Methods 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 7
- 108020004999 messenger RNA Proteins 0.000 claims description 7
- 238000012163 sequencing technique Methods 0.000 claims description 7
- 108091005804 Peptidases Proteins 0.000 claims description 6
- 239000004365 Protease Substances 0.000 claims description 6
- 238000009396 hybridization Methods 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 230000010933 acylation Effects 0.000 claims description 5
- 238000005917 acylation reaction Methods 0.000 claims description 5
- 238000003752 polymerase chain reaction Methods 0.000 claims description 5
- 230000029087 digestion Effects 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 238000003757 reverse transcription PCR Methods 0.000 claims description 3
- 239000003155 DNA primer Substances 0.000 claims description 2
- 238000012286 ELISA Assay Methods 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 210000000601 blood cell Anatomy 0.000 claims description 2
- 210000002889 endothelial cell Anatomy 0.000 claims description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 2
- 231100000590 oncogenic Toxicity 0.000 claims description 2
- 230000002246 oncogenic effect Effects 0.000 claims description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims 5
- 230000005764 inhibitory process Effects 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 241000598171 Human adenovirus sp. Species 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 230000020176 deacylation Effects 0.000 claims 1
- 238000005947 deacylation reaction Methods 0.000 claims 1
- 238000010166 immunofluorescence Methods 0.000 claims 1
- 210000004153 islets of langerhan Anatomy 0.000 claims 1
- 238000003127 radioimmunoassay Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 231100000588 tumorigenic Toxicity 0.000 claims 1
- 230000000381 tumorigenic effect Effects 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 description 294
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 103
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 103
- 210000000170 cell membrane Anatomy 0.000 description 92
- 235000018102 proteins Nutrition 0.000 description 88
- 239000005090 green fluorescent protein Substances 0.000 description 54
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 48
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 48
- 230000033001 locomotion Effects 0.000 description 43
- 239000012528 membrane Substances 0.000 description 29
- 230000006870 function Effects 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 24
- 108020001507 fusion proteins Proteins 0.000 description 24
- 230000001413 cellular effect Effects 0.000 description 23
- 102000037865 fusion proteins Human genes 0.000 description 23
- 230000004044 response Effects 0.000 description 23
- 108010074105 Factor Va Proteins 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 20
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 19
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 19
- 230000004913 activation Effects 0.000 description 19
- 229940106189 ceramide Drugs 0.000 description 19
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 19
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 19
- 239000013598 vector Substances 0.000 description 18
- 241001529936 Murinae Species 0.000 description 17
- 239000011575 calcium Substances 0.000 description 17
- 230000027455 binding Effects 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 16
- 230000001086 cytosolic effect Effects 0.000 description 15
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 14
- 210000003743 erythrocyte Anatomy 0.000 description 14
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 13
- 101001134454 Mus musculus Pancreatic triacylglycerol lipase Proteins 0.000 description 13
- 230000001640 apoptogenic effect Effects 0.000 description 13
- 239000000194 fatty acid Substances 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 210000001772 blood platelet Anatomy 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 150000004665 fatty acids Chemical class 0.000 description 12
- 230000035945 sensitivity Effects 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 239000002555 ionophore Substances 0.000 description 11
- 230000000236 ionophoric effect Effects 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 11
- 108010030416 proteoliposomes Proteins 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 10
- HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 10
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000012981 Hank's balanced salt solution Substances 0.000 description 9
- 102000003867 Phospholipid Transfer Proteins Human genes 0.000 description 9
- 108090000216 Phospholipid Transfer Proteins Proteins 0.000 description 9
- 108090000190 Thrombin Proteins 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 230000006882 induction of apoptosis Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- -1 Ca2+ ion Chemical class 0.000 description 8
- 241000283707 Capra Species 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000030833 cell death Effects 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 229960004072 thrombin Drugs 0.000 description 8
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 150000007970 thio esters Chemical class 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 108091060211 Expressed sequence tag Proteins 0.000 description 6
- 108010074860 Factor Xa Proteins 0.000 description 6
- 108010052285 Membrane Proteins Proteins 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000001747 exhibiting effect Effects 0.000 description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 108091093105 Nuclear DNA Proteins 0.000 description 5
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 5
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 210000003617 erythrocyte membrane Anatomy 0.000 description 5
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 5
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 5
- 229960005420 etoposide Drugs 0.000 description 5
- 238000013467 fragmentation Methods 0.000 description 5
- 238000006062 fragmentation reaction Methods 0.000 description 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 5
- 235000003642 hunger Nutrition 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 5
- 108010052968 leupeptin Proteins 0.000 description 5
- 230000001483 mobilizing effect Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000004481 post-translational protein modification Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000037351 starvation Effects 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- 201000000552 Scott syndrome Diseases 0.000 description 4
- 108010000499 Thromboplastin Proteins 0.000 description 4
- 102000002262 Thromboplastin Human genes 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000000799 fluorescence microscopy Methods 0.000 description 4
- 238000002825 functional assay Methods 0.000 description 4
- 229940047124 interferons Drugs 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000003805 procoagulant Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000011691 Burkitt lymphomas Diseases 0.000 description 3
- 102000011727 Caspases Human genes 0.000 description 3
- 108010076667 Caspases Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108090000144 Human Proteins Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 235000021314 Palmitic acid Nutrition 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 102000003923 Protein Kinase C Human genes 0.000 description 3
- 108090000315 Protein Kinase C Proteins 0.000 description 3
- 108010094028 Prothrombin Proteins 0.000 description 3
- 102100027378 Prothrombin Human genes 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000012288 TUNEL assay Methods 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 230000005735 apoptotic response Effects 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000002073 fluorescence micrograph Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000010661 induction of programmed cell death Effects 0.000 description 3
- 239000002198 insoluble material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000001466 metabolic labeling Methods 0.000 description 3
- 230000000869 mutational effect Effects 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000013615 primer Substances 0.000 description 3
- 229940039716 prothrombin Drugs 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000008521 reorganization Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 229920000856 Amylose Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- NZSAXLKEBXTJFL-PUODRLBUSA-N CCCCCC(C(C[N+](C)(C)C)OP([O-])(OC[C@@H](CO)O)=O)=O Chemical compound CCCCCC(C(C[N+](C)(C)C)OP([O-])(OC[C@@H](CO)O)=O)=O NZSAXLKEBXTJFL-PUODRLBUSA-N 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- LLKJHSDOKTVQNQ-IUCAKERBSA-N Glu-Gly-Arg-chloromethylketone Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(=O)CCl)CCCNC(N)=N LLKJHSDOKTVQNQ-IUCAKERBSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 102000001617 Interferon Receptors Human genes 0.000 description 2
- 108010054267 Interferon Receptors Proteins 0.000 description 2
- 108090000143 Mouse Proteins Proteins 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- VXOKDLACQICQFA-UHFFFAOYSA-N N-Desethylamiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCNCC)C(I)=C1 VXOKDLACQICQFA-UHFFFAOYSA-N 0.000 description 2
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 2
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 239000012722 SDS sample buffer Substances 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 201000011186 acute T cell leukemia Diseases 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000002457 bidirectional effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 108091036078 conserved sequence Proteins 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000002122 leukaemogenic effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 230000005894 phagocytic removal Effects 0.000 description 2
- 238000002135 phase contrast microscopy Methods 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012342 propidium iodide staining Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 101100019673 Ascaris suum CAPK gene Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 230000024704 B cell apoptotic process Effects 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- HIYAVKIYRIFSCZ-CVXKHCKVSA-N Calcimycin Chemical compound CC([C@H]1OC2([C@@H](C[C@H]1C)C)O[C@H]([C@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-CVXKHCKVSA-N 0.000 description 1
- 102000007590 Calpain Human genes 0.000 description 1
- 108010032088 Calpain Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 229940123169 Caspase inhibitor Drugs 0.000 description 1
- 241001432959 Chernes Species 0.000 description 1
- 108010078015 Complement C3b Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000010777 Disulfide Reduction Effects 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 241001503951 Phoma Species 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- MIFGOLAMNLSLGH-QOKNQOGYSA-N Z-Val-Ala-Asp(OMe)-CH2F Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 MIFGOLAMNLSLGH-QOKNQOGYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000025194 apoptotic cell clearance Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000003710 calcium ionophore Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000003796 chancre Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- GRWZHXKQBITJKP-UHFFFAOYSA-L dithionite(2-) Chemical compound [O-]S(=O)S([O-])=O GRWZHXKQBITJKP-UHFFFAOYSA-L 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 229940094991 herring sperm dna Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- HEGSGKPQLMEBJL-UHFFFAOYSA-N n-octyl beta-D-glucopyranoside Natural products CCCCCCCCOC1OC(CO)C(O)C(O)C1O HEGSGKPQLMEBJL-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000005636 thioacylation reaction Methods 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000011240 wet gel Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- cell surface PS has a role in coagulation, programmed cell death and clearance by the reticuloendothelial system.
- U.S. Serial No. 08/790,186 also describes regulation of the transmembrane distribution of PS, the role of calcium in the collapse of phospholipid asymmetry, and the role PL translocation in Scott Syndrome.
- Transformed cancer cells exhibit the capacity to proliferate through unregulated mitotic division and to resist the normal cycle of senescence and programmed cell death characteristic of most normal untransformed cells. Additionally, malignant cancer cells in vivo exhibit the capacity to evade detection or injury by the body's immune defenses, including cellular killing by cytotoxic T-lymphocytes, humoral killing by antibody and complement, and removal by macrophages and other phagocytic cells of the reticuloendothelial system.
- Fig . 7 graphs the Ca 2+ dependence of mutant human PL scramblase with amino acid substitutions in putative Ca 2+ binding site.
- Fig. 8 is a Western blot analysis of PL scramblase protein and corresponding functional assay of PL scramblase activity in various human cell lines.
- a defective form of the PL scramblase protein is expressed in the cell and that mutant PL scramblase inhibits the endogenous PL scramblase .
- endogenous PL scramblase is inactivated by deacylating essential fatty acids from the protein that are required for normal PL scramblase function in the plasma membrane.
- PL Scramblase Human PL scramblase amino acid residues in EF-hand Ca 2+ -binding motif at positions of Asp 273 , Asp 275 , Phe 277 , He 279 , Phe 281 and Asp 284 were mutated to Ala with oligonucleotide-directed mutagenesis by two rounds of PCR.
- PL scramblase-pMAL-C2 was selected as template, and the first round of PCR was performed with pairs of a complementary oligonucleotide primer containing the point mutation plus a primer complementary to a site near the ATG initial codon or TAG stop codon.
- PCR products were purified by Wizard kit.
- Proteoliposomes reconstituted with erythrocyte PL scramblase exhibit accelerated transbilayer movement of fluorescent phospholipids in response to added Ca 2+ , similar to the observed effect of calcium on the endofacial surface of the red cell membrane (Q. Zhou, et al., supra , 1997; J.G. Stout, e_t al . , J ⁇ . Clin. Invest. 99:2232-2238, 1997; Basse, et al. , J. Biol. Chem. 271:17205-17210, 1996).
- Fig. 8 depicts western blot analysis of PL scramblase in various human cell lines. Constitutive expression of PL scramblase was analyzed in the human cell lines indicated.
- Upper Panel Results obtained by Western blotting with antibody specific for PL scramblase carboxyl terminal residues E306-W318 (see Materials & Methods) . Each lane contains the total protein extract of 1.5 x 10 6 cells.
- Lower Panel Cumulative results of three separate experiments performed as follows: The cells indicated were washed and suspended at 37°C in the presence of 1.2 mM free Ca 2 ", and 2 ⁇ M A23187 was added.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention concerne une méthode d'accroissement de la viabilité des cellules ou des tissus mammifères, consistant à inhiber l'expression de la PL-scramblase native dans les cellules ou les tissus. Dans un autre mode de réalisation, l'invention concerne une méthode de réduction du potentiel métastatique et invasif ainsi que du potentiel de viabilité des cellules cancéreuses, des tissus cancéreux, ou des cellules infectées par virus, par l'augmentation de l'expression ou l'activité de la protéine PL-scramblase dans les cellules ou les tissus en question.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU23262/99A AU2326299A (en) | 1998-01-20 | 1999-01-19 | Methods and compositions to alter tissue susceptibility to immune injury, to programmed cell death, and to clearance by the reticuloendothelial system |
| EP99903179A EP1047779A2 (fr) | 1998-01-20 | 1999-01-19 | Methodes et compositions permettant de modifier la sensibilite des tissus face aux lesions immunitaires, a la mort cellulaire programmee et a la clairance par le systeme reticulo-endothelial |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7195098P | 1998-01-20 | 1998-01-20 | |
| US60/071,950 | 1998-01-20 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO1999036536A2 WO1999036536A2 (fr) | 1999-07-22 |
| WO1999036536A9 true WO1999036536A9 (fr) | 1999-11-04 |
| WO1999036536A3 WO1999036536A3 (fr) | 1999-12-09 |
Family
ID=22104619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1999/001087 WO1999036536A2 (fr) | 1998-01-20 | 1999-01-19 | Methodes et compositions permettant de modifier la sensibilite des tissus face aux lesions immunitaires, a la mort cellulaire programmee et a la clairance par le systeme reticulo-endothelial |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1047779A2 (fr) |
| AU (1) | AU2326299A (fr) |
| WO (1) | WO1999036536A2 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030139359A1 (en) * | 2001-12-04 | 2003-07-24 | Isis Pharmaceuticals Inc. | Antisense modulation of phospholipid scramblase 3 expression |
| US20030044979A1 (en) * | 2001-04-05 | 2003-03-06 | Isis Pharmaceuticals Inc. | Antisense modulation of phospholipid scramblase I expression |
| IL147812A0 (en) * | 2001-03-16 | 2002-08-14 | N S T Neurosurvival Technologi | Method for targeting chemical compounds to cells and pharmaceutical compositions used therein |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6172210B1 (en) * | 1996-04-02 | 2001-01-09 | Blood Center Research Foundation | DNA encoding phospholipid scramblase |
| US6204035B1 (en) * | 1996-04-02 | 2001-03-20 | The Blood Center Research Foundation | Methods and compositions to alter the cell surface expression of phosphatidylserine and other clot-promoting plasma membrane phospholipids |
-
1999
- 1999-01-19 WO PCT/US1999/001087 patent/WO1999036536A2/fr not_active Application Discontinuation
- 1999-01-19 EP EP99903179A patent/EP1047779A2/fr not_active Withdrawn
- 1999-01-19 AU AU23262/99A patent/AU2326299A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999036536A2 (fr) | 1999-07-22 |
| WO1999036536A3 (fr) | 1999-12-09 |
| EP1047779A2 (fr) | 2000-11-02 |
| AU2326299A (en) | 1999-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5856445A (en) | Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator | |
| US5990092A (en) | GATA-6 transcription factor: compositions and methods | |
| PT835447E (pt) | Novos péptidos e composições que modulam a apoptose | |
| WO2003037362A2 (fr) | Proteines homologues de mnk kinase impliquees dans la regulation de l'homeostase energetique et du metabolisme des organites | |
| WO1998040484A1 (fr) | Polypeptide lie a un peptide amyloide-beta intracellulaire (erab) | |
| WO1998021333A2 (fr) | Acide nucleique codant des proteines de fixation de la schwannomine et produits associes | |
| JP4403443B2 (ja) | Ｌｙ６ｈ遺伝子 | |
| US6534640B1 (en) | Methods and compositions to alter the cell surface expression of phosphatidylserine and other clot-promoting plasma membrane phospholipids | |
| US20040228866A1 (en) | Suppressor genes | |
| WO2000023100A9 (fr) | Genes et proteines destines a la prevention et therapie de maladies renales et de troubles associes | |
| Rother et al. | Expression of recombinant transmembrane CD59 in paroxysmal nocturnal hemoglobinuria B cells confers resistance to human complement | |
| WO1999036536A9 (fr) | Methodes et compositions permettant de modifier la sensibilite des tissus face aux lesions immunitaires, a la mort cellulaire programmee et a la clairance par le systeme reticulo-endothelial | |
| EP0900275B1 (fr) | Procede et reactifs servant a moduler l'apoptose | |
| WO1998039434A9 (fr) | Procede et reactifs servant a moduler l'apoptose | |
| JPH11507845A (ja) | 神経細胞付着分子スプライシング変種 | |
| HUT74413A (en) | A novel tumor suppressor gene | |
| EP0943096A1 (fr) | PREPARATION D'UNE PROTEINE QUI CONTROLE LE MOUVEMENT Ca2+ -DEPENDANT DES PHOSPHOLIPIDES DES MEMBRANES PLASMIQUES A TRAVERS LES COUCHES DOUBLES ET INHIBITEURS DE CETTE PROTEINE | |
| US7256321B2 (en) | Intracellular modulators of apoptopic cell death pathways | |
| CN101228184A (zh) | 变体iaspp多肽及筛选测定 | |
| WO2002079238A2 (fr) | Proteine bisulfure isomerase et proteines homologues transporteuses d'abc impliquees dans la regulation de l'hemostase energetique | |
| US20030104443A1 (en) | AFAP sequences, polypeptides, antibodies and methods | |
| Tyrsin | Role of Raf family members in mouse development | |
| CA2252422A1 (fr) | Procede et reactifs servant a moduler l'apoptose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| AK | Designated states |
Kind code of ref document: C2 Designated state(s): AU CA JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| COP | Corrected version of pamphlet |
Free format text: PAGES 1/16-16/16, DRAWINGS, REPLACED BY NEW PAGES 1/20-20/20; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1999903179 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 09600535 Country of ref document: US |
|
| WWP | Wipo information: published in national office |
Ref document number: 1999903179 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1999903179 Country of ref document: EP |